Jefferies Lifts Target on Amarin (AMRN) After Positive Patent Actions

Jefferies boosted its price target on Buy-rated Amarin Corporation (NASDAQ: AMRN) from $24 to $26 after the patent office (PTO) posted unexpected positive office actions on three key patent applications based on MARINE: the core ‘889 application and two continuation applications ‘408 and ’14.

"We believe these actions should lead to near-term issuance of these patents, which could provide AMR101 protection through 2030. We remain bullish on near-term approval of AMR101."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $13.16 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UnitedHealth Group (UNH) PT Raised to $475 at Piper Sandler
• Ligand Pharma (LGND) PT Raised to $340 at RBC Capital
• Goldman Sachs (GS) PT Raised to $1,130 at Keefe, Bruyette & Woods